

Curriculum vitae


PERSONAL INFORMATION

Gionata Fiorino

 via Manzoni 56, 20089 Rozzano (Italy)

 +390282245555

 gionataf@gmail.com

 it.linkedin.com/pub/gionata-fiorino/35/7b9/897/ <http://www.humanitas.it/pazienti/info/i-nostri-medici/302-fiorino-gionata>

Sex Male | Date of birth 24/10/1979 | Nationality Italian

POSITION

Senior Consultant - IBD Center, Dept. of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy

WORK EXPERIENCE

28/07/2017–Present

Adjunct Teaching Professor

Department of Biomedical Sciences, Humanitas University, Rozzano, Milan (Italy)

01/01/2017–Present

Senior Consultant - IBD Specialist

IRCCS Humanitas
via Manzoni 56, 20089 Rozzano (Italy)

Clinical management of patients with inflammatory bowel disease (IBD). Clinical Research on IBD.

01/01/2010–31/12/2016

Consultant - IBD Specialist

IBD Center, Dept. of Gastroenterology, IRCCS Humanitas
via Manzoni 56, 20089 Rozzano (Italy)

Clinical management of patients with inflammatory bowel disease (IBD). Clinical Research on IBD.

01/09/2008–30/04/2009

Clinical Research Fellow

IRCCS Humanitas
via Manzoni 56, 20089 Rozzano (Italy)

Clinical Research on IBD.

01/05/2005–31/08/2008

General Practitioner substitute

00100 Roma (Italy)

General Medicine

EDUCATION AND TRAINING

19/10/2017–20/10/2017

Advanced Course on Management in Gastroenterology and Immunology

LIUC University, Castellanza (Italy)

- Management of healthcare resources, budget impact
- Presentation and negotiation skills
- Legal issues in clinical practice

EQF level 8

01/01/2010–31/12/2012	Philosophiae Doctor University di Messina, Messina (Italy) Clinical and biomolecular hepatogastroenterology for children and adults	Livello 6 ISCED
01/11/2005–19/11/2009	Specialist in Gastroenterology Sapienza, University of Rome, Rome (Italy) Gastroenterology	Livello 6 ISCED
19/10/1998–28/10/2004	Degree in Medicine and Surgery Università Cattolica del Sacro Cuore - Rome Largo Gemelli 1, 00168 Rome (Italy)	Livello 5B ISCED
01/09/1993–31/07/1998	High School on Humanities Liceo Classico "Cagnazzi" Piazza Zanardelli, 70022 Altamura (Italy)	Livello 3B ISCED
11/2011–03/2012	Advanced Course on systematic revisions, metanalysis and guidelines production. Cochrane Collaboration, Mario Negri Institute - University of Milan, Milan (Italy) <ul style="list-style-type: none"> - Systematic review - Literature search - Assessment of quality of data - Extraction and data meta-analysis - GRADE methodology - Assessment of evidence - Consensus and guidelines production 	
09/2008	Experimental Medicine Division - Univrsity of Oxford, Oxford (United Kingdom) Master Class in Crohn's Disease	
09/2007	Experimental Medicine Division - University of Oxford, Oxford (United Kingdom) Master Class in Ulcerative Colitis	
04/2007–06/2007	Università Cattolica del Sacro Cuore, Rome (Italy) Advanced Course on Endoscopy and Videocapsule endoscopy.	
01/2006	Italian Association of Liver - Italian Society of Gastroenterology and Endoscopy, Chianciano Terme (Italy) Course on Portal Hypertension	

09/2004–10/2004

Bichat-Claude Bernard Hospital, Paris (France)
Training in Gastroenterology, Digestive Endoscopy and Proctology

03/2004

Bichat-Claude Bernard Hospital, Paris (France)
Training in Gastroenterology, Digestive Endoscopy and Proctology

06/09/2003–31/10/2003

Bichat-Claude Bernard Hospital, Paris (France)
Training in Gastroenterology, Digestive Endoscopy and Proctology

19/09/2002–19/10/2002

Bichat-Claude Bernard Hospital, Paris (France)
Training in Gastroenterology, Digestive Endoscopy and Proctology

PERSONAL SKILLS

Mother tongue(s) Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C2
French	B2	B2	B1	B1	A2
Spanish	B2	B2	A2	A2	A2
Dutch	A1	A2	A1	A2	A2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Communication skills 2010-present: Speaker in more than 100 National and International Meetings

Organisational / managerial skills Organizing working groups and collaborative studies.

Digital skills Microsoft Windows, Office and management of electronic databases.

Driving licence B

ADDITIONAL INFORMATION

Publications

1. Bonovas S, Nikolopoulos G K, Lytras T, **Fiorino G**, Peyrin-Biroulet L, Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis Br J Clin Pharmacol 2017;
2. Allocca M, **Fiorino G**, Danese S. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Dig Dis Sci 2017; 62: 2964-2965
3. Ungaro F, Tacconi C, Massimino L, Corsetto P A, Correale C, Fonteyne P, Piontini A, Garzarelli V, Calcaterra F, Della Bella S, Spinelli A, Carvello M, Rizzo A M, Vetrano S, Petti L, **Fiorino G**, Furfaro F,

- Mavilio D, Maddipati K R, Malesci A, Peyrin-Biroulet L, D'Alessio S, Danese S. MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice *Gastroenterology* 2017; 153: 1363-1377 e6
4. **Fiorino G**, Correale C, Radice S, Allocca M, Furfaro F, Gilardi D, Nagore D, Del Rio L, Pascual J, Martinez A, Danese S. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients *Aliment Pharmacol Ther* 2017; 46: 903-905
 5. Menichetti J, **Fiorino G**, Vegni E. Personalizing psychological treatment along the IBD journey: From diagnosis to surgery *Curr Drug Targets* 2017;
 6. Furfaro F, Gilardi D, Allocca M, Cicerone C, Correale C, **Fiorino G**, Danese S. IL-23 Blockade for Crohn's disease: next generation of anti-cytokine therapy *Expert Rev Clin Immunol* 2017; 13: 457-467
 7. Bonovas S, **Fiorino G**, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease *Aliment Pharmacol Ther* 2017; 45: 1179-1192
 8. **Fiorino G**, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L, Danese S. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome *J Crohns Colitis* 2017; 11: 274-280
 9. Bonovas S, **Fiorino G**, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply *Aliment Pharmacol Ther* 2017; 45: 1554-1555
 10. Gomollon F, Dignass A, Annesse V, Tilg H, Van Assche G, Lindsay J O, Peyrin-Biroulet L, Cullen G J, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, **Fiorino G**, Juillerat P, Mantzaris G J, Rizzello F, Vavricka S, Gionchetti P. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management *J Crohns Colitis* 2017; 11: 3-25
 11. Fries W, Viola A, Manetti N, Frankovic I, Pugliese D, Monterubbianesi R, Scalisi G, Aratari A, Cantoro L, Cappello M, Samperi L, Saibeni S, Casella G, Mocchi G, Rea M, Furfaro F, Contaldo A, Magarotto A, Calella F, Manguso F, Inserra G, Privitera A C, Principi M, Castiglione F, Caprioli F, Ardizzone S, Danese S, Papi C, Bossa F, Kohn A, Armuzzi A, D'Inca R, Annesse V, Alibrandi A, Bonovas S, **Fiorino G**. Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study" *Dig Liver Dis* 2017; 49: 17-23
 12. Danese S, **Fiorino G**, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos P L, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update *J Crohns Colitis* 2017; 11: 26-34
 13. Katsanos K H, Domenech E, Rahier J F, Kopylov U, **Fiorino G**, Rogler G, Louis E, Ben-Horin S. Making a Case for Case Reports: The ECCO-CONFER Viewpoint on Investigating Rare Events in a Medical World Reigned by Group-comparative Statistics *J Crohns Colitis* 2017; 11: 256-257
 14. **Fiorino G**, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, D'Inca R, Lionetti P, Cantoro L, Fries W, Annunziata M L, Costa F, Terpin M M, Biancone L, Cortezzi C C, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annesse V. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar *Inflamm Bowel Dis* 2017; 23: 233-243
 15. Sigall-Boneh R, Levine A, Lomer M, Wierdsma N, Allan P, **Fiorino G**, Gatti S, Jonkers D, Kierkus J, Katsanos K H, Melgar S, Yuksel E S, Whelan K, Wine E, Gerasimidis K. Research Gaps in Diet and Nutrition in Inflammatory Bowel Disease. A Topical Review by D-ECCO Working Group [Dietitians of ECCO] *J Crohns Colitis* 2017; 11: 1407-1419
 16. Avila-Ribeiro P, **Fiorino G**, Danese S. The experience with biosimilars of infliximab in inflammatory bowel disease *Curr Pharm Des* 2017;
 17. Argollo M, **Fiorino G**, Hindryckx P, Peyrin-Biroulet L, Danese S. Novel therapeutic targets for inflammatory bowel disease *J Autoimmun* 2017; 85: 103-116
 18. Danese S, **Fiorino G**, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials *Gut* 2017; 66: 2179-2187
 19. Gilardi D, **Fiorino G**, Furfaro F, Alfieri M F, Orlandi I, Allocca M, Danese S. Comparison of two methods for the in-vivo diagnosis of *Helicobacter pylori* infection using a tablet of ¹³C-urea *Minerva Gastroenterol Dietol* 2017; 63: 319-326
 20. Allocca M, Bonifacio C, **Fiorino G**, Spinelli A, Furfaro F, Balzarini L, Bonovas S, Danese S. Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience *Dig Liver Dis* 2017; 49: 872-877

21. Danese S, **Fiorino G**, Peyrin-Biroulet L. Filgotinib in Crohn's Disease: JAK Is Back *Gastroenterology* 2017; 153: 603-605
22. **Fiorino G**, Bonovas S, Cicerone C, Allocca M, Furfaro F, Correale C, Danese S. The safety of biological pharmacotherapy for the treatment of ulcerative colitis *Expert Opin Drug Saf* 2017; 16: 437-443
23. Allocca M, Landi R, Bonovas S, **Fiorino G**, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A, Danese S. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting *Digestion* 2017; 96: 166-172
24. Vuitton L, Marteau P, Sandborn W J, Levesque B G, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, **Fiorino G**, Travis S, Mary J Y, Peyrin-Biroulet L. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials *Gut* 2016; 65: 1447-55
25. Bonovas S, **Fiorino G**, Allocca M, Lytras T, Nikolopoulos G K, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis *Clin Gastroenterol Hepatol* 2016; 14: 1385-1397 e10
26. **Fiorino G**, Cortes P N, Ellul P, Felice C, Karatzas P, Silva M, Lakatos P L, Bossa F, Ungar B, Sebastian S, Furfaro F, Karmiris K, Katsanos K H, Muscat M, Christodoulou D K, Maconi G, Kopylov U, Magro F, Mantzaris G J, Armuzzi A, Bosca-Watts M M, Ben-Horin S, Bonovas S, Danese S. Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study *Clin Gastroenterol Hepatol* 2016; 14: 1426-1432 e1
27. **Fiorino G**, Danese S. Diagnostic Delay in Crohn's Disease: Time for Red Flags *Dig Dis Sci* 2016; 61: 3097-3098
28. Danese S, **Fiorino G**, Michetti P. Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey *J Crohns Colitis* 2016; 10: 1362-1365
29. **Fiorino G**, Danese S. Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? *J Crohns Colitis* 2016; 10: 1257-1258
30. Allocca M, **Fiorino G**, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S. Biologic therapies in ulcerative colitis: primi inter pares? *Curr Drug Targets* 2016;
31. Bonovas S, **Fiorino G**, Lytras T, Malesci A, Danese S. Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials *World J Gastroenterol* 2016; 22: 4594-603
32. Furfaro F, **Fiorino G**, Allocca M, Gilardi D, Danese S. Emerging therapeutic targets and strategies in Crohn's disease *Expert Rev Gastroenterol Hepatol* 2016; 10: 735-44
33. Kopylov U, Katsanos K H, van der Woude C J, Karmiris K, Hernandez V, Odes S, Papamichael K, Koutroubakis I E, Bojic D, Kaimakliotis I, **Fiorino G**, Papageorgiou N, Pineda J R, Strongili K, Sanroman L, Mantzaris G J, Jojic N, Paspatis G, Christodoulou D K, Ben-Horin S, Tsianos E V. European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis *Eur J Gastroenterol Hepatol* 2016; 28: 802-6
34. **Fiorino G**, Gilardi D, Danese S. The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes *Therap Adv Gastroenterol* 2016; 9: 503-12
35. Bonovas S, **Fiorino G**, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S. Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials *Medicine (Baltimore)* 2016; 95: e2308
36. Lopez-Posadas R, Becker C, Gunther C, Tenzer S, Amann K, Billmeier U, Atreya R, **Fiorino G**, Vetrano S, Danese S, Ekici A B, Wirtz S, Thonn V, Watson A J, Brakebusch C, Bergo M, Neurath M F, Atreya I. Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation *J Clin Invest* 2016; 126: 611-26
37. Ellul P, Zammita S C, Katsanos K H, Cesarini M, Allocca M, Danese S, Karatzas P, Moreno S C, Kopylov U, **Fiorino G**, Torres J, Lopez-Sanroman A, Caruana M, Zammit L, Mantzaris G. Perception of Reproductive Health in Women with Inflammatory Bowel Disease *J Crohns Colitis* 2016; 10: 886-91
38. **Fiorino G**, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing Collateral Damage in Crohn's Disease: The Lemann Index *J Crohns Colitis* 2016; 10: 495-500
39. **Fiorino G**, Fazio M, Danese S. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile? *Expert Rev Clin Immunol* 2016; 12: 361-3
40. Danese S, Peyrin-Biroulet L, **Fiorino G**. Predicting future disease course in Crohn's disease by colonoscopy or magnetic resonance: which is the crystal ball? *Gut* 2015; 64: 1347-8

41. **Fiorino G**, Omodei P D. Psoriasis and Inflammatory Bowel Disease: Two Sides of the Same Coin? *J Crohns Colitis* 2015; 9: 697-8
42. Peyrin-Biroulet L, Sandborn W, Sands B E, Reinisch W, Bemelman W, Bryant R V, D'Haens G, Dotan I, Dubinsky M, Feagan B, **Fiorino G**, Gearry R, Krishnareddy S, Lakatos P L, Loftus E V, Jr., Marteau P, Munkholm P, Murdoch T B, Ordas I, Panaccione R, Riddell R H, Ruel J, Rubin D T, Samaan M, Siegel C A, Silverberg M S, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel J F. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target *Am J Gastroenterol* 2015; 110: 1324-38
43. **Fiorino G**, Allocca M, Danese S. Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? *Clin Gastroenterol Hepatol* 2015; 13: 1767-9
44. Danese S, **Fiorino G**, Peyrin-Biroulet L. Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way? *Gastroenterology* 2015; 149: 1121-3
45. Annese V, Beaugerie L, Egan L, Biancone L, Bolling C, Brandts C, Dierickx D, Dummer R, **Fiorino G**, Gornet J M, Higgins P, Katsanos K H, Nissen L, Pellino G, Rogler G, Scaldaferrì F, Szymanska E, Eliakim R. European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies *J Crohns Colitis* 2015; 9: 945-65
46. Gilardi D, **Fiorino G**, Allocca M, Bravata I, Danese S. Golimumab: clinical update on its use for ulcerative colitis *Drugs Today (Barc)* 2015; 51: 171-84
47. Moja L, Danese S, **Fiorino G**, Del Giovane C, Bonovas S. Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease *Aliment Pharmacol Ther* 2015; 41: 1055-65
48. Quetglas E G, Armuzzi A, Wigge S, **Fiorino G**, Barnscheid L, Froelich M, Danese S. Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment *Eur J Clin Pharmacol* 2015; 71: 773-99
49. Pariente B, Mary J Y, Danese S, Chowers Y, De Cruz P, D'Haens G, Loftus E V, Jr., Louis E, Panes J, Scholmerich J, Schreiber S, Vecchi M, Branche J, Bruining D, **Fiorino G**, Herzog M, Kamm M A, Klein A, Lewin M, Meunier P, Ordas I, Strauch U, Tontini G E, Zagdanski A M, Bonifacio C, Rimola J, Nachury M, Leroy C, Sandborn W, Colombel J F, Cosnes J. Development of the Lemann index to assess digestive tract damage in patients with Crohn's disease *Gastroenterology* 2015; 148: 52-63 e3
50. Bravata I, **Fiorino G**, Allocca M, Repici A, Danese S. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease *Scand J Gastroenterol* 2015; 50: 113-20
51. van der Woude C J, Ardizzone S, Bengtson M B, **Fiorino G**, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders A G, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z, Magro F. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease *J Crohns Colitis* 2015; 9: 107-24
52. Bravata I, Allocca M, **Fiorino G**, Danese S. Integrins and adhesion molecules as targets to treat inflammatory bowel disease *Curr Opin Pharmacol* 2015; 25: 67-71
53. Danese S, **Fiorino G**, Mary J Y, Lakatos P L, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn W J, Travis S P, Vermeire S, Peyrin-Biroulet L, Colombel J F. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative *J Crohns Colitis* 2015; 9: 601-6
54. **Fiorino G**, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S. Bowel Damage as Assessed by the Lemann Index is Reversible on Anti-TNF Therapy for Crohn's Disease *J Crohns Colitis* 2015; 9: 633-9
55. Fernandes C, Allocca M, Danese S, **Fiorino G**. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease *Immunotherapy* 2015; 7: 175-90
56. Giancaspero T A, Colella M, Brizio C, Difonzo G, **Fiorino G** M, Leone P, Brandsch R, Bonomi F, Iametti S, Barile M. Remaining challenges in cellular flavin cofactor homeostasis and flavoprotein biogenesis *Front Chem* 2015; 3: 30
57. Nuti F, **Fiorino G**, Danese S. Adalimumab for the treatment of pediatric Crohn's disease *Expert Rev Clin Immunol* 2015; 11: 963-72
58. Gilardi D, **Fiorino G**, Genua M, Allocca M, Danese S. Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? *Expert Rev Gastroenterol Hepatol* 2014; 8: 835-46
59. Danese S, **Fiorino G**, Michetti P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal

- antibodies among members of the European Crohn's and Colitis Organization *J Crohns Colitis* 2014; 8: 1548-50
60. Lazzaro C, Cappello M, Cortelezzi C, Costantino G, **Fiorino G**, Mastronardi M, Giannotta M, Galletti B, Cicala M, Vadala di Prampero S, Gualberti G, Caprioli F, Gasbarrini A, Fattore G. A Health Technology-Related Cost Description Concerning Italian Ibd Centres Dealing With Crohn's Disease Results From Sole Study Value Health 2014; 17: A370
61. Lazzaro C, Cappello M, Cortelezzi C, Costantino G, **Fiorino G**, Mastronardi M, Giannotta M, Galletti B, Cicala M, Vadala di Prampero S, Gualberti G, Caprioli F, Gasbarrini A, Meregaglia M. Health-Related Quality of Life in Italian Patients With Moderate and Severe Crohn's Disease: Interim Results from the Sole Study Value Health 2014; 17: A570-1
62. Danese S, **Fiorino G**, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, Bonovas S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis *Ann Intern Med* 2014; 160: 704-11
63. **Fiorino G**, Danese S. Commentary: Adjunct antibiotic combination therapy for ulcerative colitis—is it time to investigate *Fusobacterium varium*? *Aliment Pharmacol Ther* 2014; 39: 1333
64. **Fiorino G**, Danese S. The biosimilar road in inflammatory bowel disease: the right way? *Best Pract Res Clin Gastroenterol* 2014; 28: 465-71
65. **Fiorino G**, Girolimoni G, Lapadula G, Orlando A, Danese S, Olivieri I. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SiDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper *Autoimmun Rev* 2014; 13: 751-5
66. Allocca M, **Fiorino G**, Vermeire S, Reinisch W, Cataldi F, Danese S. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target *Expert Rev Clin Immunol* 2014; 10: 885-95
67. **Fiorino G**, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents *Autoimmun Rev* 2014; 13: 15-9
68. Spinelli A, **Fiorino G**, Bazzi P, Sacchi M, Bonifacio C, De Bastiani S, Malesci A, Balzarini L, Peyrin-Biroulet L, Montorsi M, Danese S. Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease *J Gastrointest Surg* 2014; 18: 83-90; discussion 90-1
69. **Fiorino G**, Allocca M, Danese S. Commentary: anaemia in inflammatory bowel disease—the most common and ignored extra intestinal manifestation *Aliment Pharmacol Ther* 2014; 39: 227-8
70. Cesarini M, Katsanos K, Papamichael K, Ellul P, Lakatos P L, Caprioli F, Kopylov U, Tsianos E, Mantzaris G J, Ben-Horin S, Danese S, **Fiorino G**. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study *Dig Liver Dis* 2014; 46: 135-9
71. **Fiorino G**, Danese S. Etrolizumab in ulcerative colitis: tightening leukocyte traffic control in the inflamed mucosa *Gastroenterology* 2014; 147: 1433-5
72. Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, **Fiorino G**, Nardone O M, De Vitis I, Papa A, Rapaccini G L, Guidi L. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis *Inflamm Bowel Dis* 2014; 20: 1368-74
73. **Fiorino G**, Gilardi D, Naccarato P, Sociale O R, Danese S. Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis *Dig Liver Dis* 2014; 46: 330-4
74. Leone D, Menichetti J, **Fiorino G**, Vegni E. State of the art: psychotherapeutic interventions targeting the psychological factors involved in IBD *Curr Drug Targets* 2014; 15: 1020-9
75. Danese S, **Fiorino G**, Fernandes C, Peyrin-Biroulet L. Catching the therapeutic window of opportunity in early Crohn's disease *Curr Drug Targets* 2014; 15: 1056-63
76. Allocca M, **Fiorino G**, Danese S. Iron deficiency: the hidden miscreant in inflammatory bowel disease *Curr Drug Targets* 2014; 15: 1011-9
77. Allocca M, **Fiorino G**, Danese S. Commentary: antibodies reacting with the infliximab Fab portion—something new? *Aliment Pharmacol Ther* 2013; 38: 552
78. Jovani M, **Fiorino G**, Danese S. Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside *Curr Drug Targets* 2013; 14: 1444-52
79. **Fiorino G**, Bonifacio C, Padrenostro M, Sposta F M, Spinelli A, Malesci A, Balzarini L, Peyrin-Biroulet L, Danese S. Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for

the assessment of disease activity and complications in ileo-colonic Crohn's disease *Dig Dis Sci* 2013; 58: 3246-55

80. Allocca M, Jovani M, **Fiorino G**, Schreiber S, Danese S. Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target *Curr Drug Targets* 2013; 14: 1508-21

81. Cammarota T, Ribaldone D G, Resegotti A, Repici A, Danese S, **Fiorino G**, Sarno A, Robotti D, Debari P, Bonenti G, Pellicano R, Andrealli A, Sapone N, Simondi D, Bresso F, Astegiano M. Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease *Scand J Gastroenterol* 2013; 48: 552-5

82. Peyrin-Biroulet L, **Fiorino G**, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? *Nat Rev Gastroenterol Hepatol* 2013; 10: 345-51

83. Spinelli A, Bazzi P, Sacchi M, Danese S, **Fiorino G**, Malesci A, Gentilini L, Poggioli G, Montorsi M. Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis *J Gastrointest Surg* 2013; 17: 126-32; discussion p 132

84. Jovani M, **Fiorino G**, Danese S. Commentary: associations between immune activation, intestinal permeability and irritable bowel syndrome *Aliment Pharmacol Ther* 2013; 37: 277-8

85. Iborra M, Bernuzzi F, Correale C, Vetrano S, **Fiorino G**, Beltran B, Marabita F, Locati M, Spinelli A, Nos P, Invernizzi P, Danese S. Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease *Clin Exp Immunol* 2013; 173: 250-8

86. Armuzzi A, Pugliese D, Danese S, Rizzo G, Felice C, Marzo M, Andrisani G, **Fiorino G**, Sociale O, Papa A, De Vitis I, Rapaccini G L, Guidi L. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission *Inflamm Bowel Dis* 2013; 19: 1065-72

87. Indriolo A, Fagioli S, Pasulo L, **Fiorino G**, Danese S, Ravelli P. Letter: infliximab therapy in inflammatory bowel disease patients after liver transplantation *Aliment Pharmacol Ther* 2013; 37: 840-2

88. Cesarini M, **Fiorino G**. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease—an update *Expert Rev Clin Immunol* 2013; 9: 301-6

89. Allocca M, **Fiorino G**, Danese S. Cross-sectional imaging modalities in Crohn's disease *Dig Dis* 2013; 31: 199-201

90. Chevaux J B, **Fiorino G**, Frederic M, Peyrin-Biroulet L. Capsule endoscopy in Crohn's disease *Curr Drug Targets* 2012; 13: 1261-7

91. **Fiorino G**, Cesarini M, Malesci A, Danese S, Sorrentino D. The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease *Curr Drug Targets* 2012; 13: 1273-9

92. **Fiorino G**, Peyrin-Biroulet L, Danese S. Bowel damage assessment in Crohn's disease by magnetic resonance imaging *Curr Drug Targets* 2012; 13: 1300-7

93. Danese S, **Fiorino G**, Rutella S. Regulatory T-cell therapy for Crohn's disease: in vivo veritas *Gastroenterology* 2012; 143: 1135-8

94. **Fiorino G**, Peyrin-Biroulet L, Naccarato P, Szabo H, Sociale O R, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study *Inflamm Bowel Dis* 2012; 18: 1042-7

95. De Cassan C, **Fiorino G**, Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects? *Dig Dis* 2012; 30: 368-75

96. Fabro M, Szabo H, Terrosu G, Avellini C, Tabuso M, **Fiorino G**, Sorrentino D. Acute severe colitis: infliximab and/or cyclosporine? *Curr Drug Targets* 2011; 12: 1448-53

97. **Fiorino G**, Cesarini M, Indriolo A, Malesci A. Mucosal healing in ulcerative colitis: where do we stand? *Curr Drug Targets* 2011; 12: 1417-23

98. **Fiorino G**, Cesarini M, Danese S. Biological therapy for ulcerative colitis: what is after anti-TNF *Curr Drug Targets* 2011; 12: 1433-9

99. **Fiorino G**, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn's disease—current and future clinical applications *Nat Rev Gastroenterol Hepatol* 2011; 9: 23-31

100. **Fiorino G**, Bonifacio C, Peyrin-Biroulet L, Minuti F, Repici A, Spinelli A, Fries W, Balzarini L, Montorsi M, Malesci A, Danese S. Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease *Inflamm Bowel Dis* 2011; 17: 1073-80

101. Nunes T, **Fiorino G**, Danese S, Sans M. Familial aggregation in inflammatory bowel disease: is it

genes or environment? *World J Gastroenterol* 2011; 17: 2715-22

102. Spinelli A, Sacchi M, **Fiorino G**, Danese S, Montorsi M. Risk of postoperative recurrence and postoperative management of Crohn's disease *World J Gastroenterol* 2011; 17: 3213-9

103. Danese S, **Fiorino G**, Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy *Aliment Pharmacol Ther* 2011; 34: 1-10

104. **Fiorino G**, Peyrin-Biroulet L, Repici A, Malesci A, Danese S. Adalimumab in ulcerative colitis: hypes and hopes *Expert Opin Biol Ther* 2011; 11: 109-16

105. Kopylov U, Mantzaris G J, Katsanos K H, Reenaers C, Ellul P, Rahier J F, Israeli E, Lakatos P L, **Fiorino G**, Cesarini M, Tsianos E V, Louis E, Ben-Horin S. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab *Aliment Pharmacol Ther* 2011; 33: 349-57

106. Rahier J F, Papay P, Salleron J, Sebastian S, Ellul P, Teich N, **Fiorino G**, Blaha B, Garcia-Sanchez V, Haas T, Van Gossum A, Abitbol V, Yazdanpanah Y, Chaparro M C. Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series *Aliment Pharmacol Ther* 2011; 33: 499-500

107. Rahier J F, Papay P, Salleron J, Sebastian S, Marzo M, Peyrin-Biroulet L, Garcia-Sanchez V, Fries W, van Asseldonk D P, Farkas K, de Boer N K, Sipponen T, Ellul P, Louis E, Peake S T, Kopylov U, Maul J, Makhoul B, **Fiorino G**, Yazdanpanah Y, Chaparro M. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy *Gut* 2011; 60: 456-62

108. Rutella S, **Fiorino G**, Vetrano S, Correale C, Spinelli A, Pagano N, Arena V, Maggiano N, Repici A, Malesci A, Danese S. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease *Am J Gastroenterol* 2011; 106: 762-70

109. **Fiorino G**, Szabo H, Fries W, Malesci A, Peyrin-Biroulet L, Danese S. Adalimumab in Crohn's disease: tips and tricks after 5 years of clinical experience *Curr Med Chem* 2011; 18: 1230-8

110. Danese S, **Fiorino G**, Angelucci E, Vetrano S, Pagano N, Rando G, Spinelli A, Malesci A, Repici A. Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study *World J Gastroenterol* 2010; 16: 2396-400

111. **Fiorino G**, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease *Expert Rev Clin Immunol* 2010; 6: 567-72

112. Szabo H, **Fiorino G**, Spinelli A, Rovida S, Repici A, Malesci A C, Danese S. Review article: anti-fibrotic agents for the treatment of Crohn's disease - lessons learnt from other diseases *Aliment Pharmacol Ther* 2010; 31: 189-201

113. Sorrentino D, Paviotti A, **Fiorino G**. Anti-TNF's for postoperative recurrence in Crohn's disease: the if's and how's *Curr Drug Targets* 2010; 11: 219-26

114. **Fiorino G**, Rovida S, Correale C, Malesci A, Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? *Curr Drug Targets* 2010; 11: 249-60

115. **Fiorino G**, Fries W, De La Rue S A, Malesci A C, Repici A, Danese S. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut *Curr Med Chem* 2010; 17: 1851-7

116. **Fiorino G**, Allez M, Malesci A, Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease *Aliment Pharmacol Ther* 2009; 29: 921-7

117. Cesarini M, Angelucci E, **Fiorino G**, Crudeli A, Vernia P, Caprilli R. Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned *Inflamm Bowel Dis* 2008; 14: 1165-6

Memberships

January 2018-current: Chair of the Scientific Committee of the Italian Group of Inflammatory Bowel Disease (IG-IBD)

October 2017-current: Coordinator of the GRADE-based ECCO Guidelines on Therapeutics in Crohn's Disease

October 2016-October 2017: Working Group Leader for the ECCO "Diagnostic and Monitoring Consensus"

October 2016-current: Member of the ECCO CONFER

February 2015-current: Member of the ECCO GuiCom

February 2015-current: Member of the Editorial Board of the Journal of Crohn's and Colitis (JCC)

January 2014-January 2017: Member of the Scientific Committee of the Italian Group of Inflammatory Bowel Disease (IG-IBD)

Jul 2013-Sep 2014: Member of ECCO Consensus for European Guidelines on Malignancies in IBD

April 3, 2014: Fellow member of the IO-IBD Consensus "Treat to Target"

March 2013-October 2013: Member of ECCO Consensus for European Guidelines on pharmacological maintenance of remission in Crohn's disease

March 2013-October 2013: Member of ECCO Consensus for European Guidelines on lactation in Inflammatory Bowel Disease

June 2010: Member of WHO Consensus Conference on "ICF Core Sets for IBD" – Nottwil (CH)

October 2006 - March 2009 Chairman of Young European Crohn's Colitis Organization (Y-ECCO)

2006-current: Member of European Crohn's Colitis Organization (ECCO)

2006-current: Member of Italian Group - Inflammatory Bowel Disease (IG-IBD)

2005-2009: Member of Italian Society of Gastroenterology and Digestive Endoscopy (SIGE)

19 July 2012-current: Medical License - OMCeO Milano n. 42409

30 March 2005-19 July 2012: Medical License - OMCeO Bari n. 12903

Seminars February 2009 - Faculty YECCO Workshop "How to set up a clinical trial" – Hamburg (D)
June 2008 Supervisor for medical thesis – Sapienza, University of Rome (I)
May 2008 Tutor IG-IBD Course – Mondello (I)
March 2008 - Faculty YECCO Workshop "Presentation skills" – Lyon (F)

Projects 2014 - Bibliographic Fellow for the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) STRIDE (Selecting therapeutic targets in inflammatory bowel disease) initiative
2010 - Principal investigator in the Validation Study of Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
2008-current Sub-investigator in more than 50 phase 1-4 multicenter randomized clinical trials

Honours and awards 2014: Best abstract, Digital Oral Poster Presentation, Session 4, ECCO Congress, Copenhagen (DK)

2017 ECCO Vifor Grant on "Efficacy of iron supplementation in patients with inflammatory bowel disease and chronic fatigue" - Euro 40,000

Citations 05/Oct/2017: H-Index 23 (Scopus)